March 24, 2020
A human trial being held in Washington State to research a promising drug designed to fight COVID-19 is reportedly going better than expected, and it’s possible that a handful of infected patients – likely health-care workers – could be administered the drug by the fall.
Stephane Bancel, the biotech’s chief executive, told Goldman Sachs on Friday that mRNA-1273 could be made available to a few patients, likely health-care workers suffering from COVID-19, under emergency use authorization, according to a statement from the company picked up by Bloomberg.
The vaccine was developed in partnership with Moderna and the National Institute of Allergy and Infectious Diseases, with human testing starting earlier this month.
Moderna is ramping up production so it’s ready to produce millions of doses of its experimental vaccine if the vaccine is found to be useful in curing and preventing the virus. A commercially-available vaccine isn’t expected for at least a year.
Israeli scientists over the past few weeks had claimed that they could have a virus ready in a matter of weeks or months, though these claims have largely been debunked. Still, more than 20 companies are racing to produce a cure for the novel coronavirus.
A recent article by the Jerusalem Post outlined the companies behind some of the more promising efforts to develop a treatment or vaccine.
This article was posted: Tuesday, March 24, 2020 at 4:06 am